Extracellular vesicles (EVs) are biological nanoparticles with important roles in intercellular communication and pathophysiology. Their capacity to transfer biomolecules between cells has sparked efforts to bioengineer EVs as drug delivery vehicles. However, a better understanding of EV biogenesis mechanisms and function is required to unleash their considerable therapeutic potential. Here we demonstrate a novel role for GAPDH, a glycolytic enzyme, in EV assembly and secretion, and we exploit these findings to develop a GAPDHbased methodology to load therapeutic siRNAs onto EVs for targeted drug delivery to the brain. In a series of experiments, we observe high levels of GAPDH binding to the outer surface of EVs via a phosphatidylserine binding motif, designated as G58, and discover that the tetrameric nature of GAPDH promotes extensive EV aggregation. Studies in a Drosophila EV biogenesis model demonstrate that GAPDH is absolutely required for normal generation of intraluminal vesicles in endosomal compartments and promotes vesicle clustering both inside and outside the cell. Fusing a GAPDH-derived G58 peptide to dsRNA-binding motifs permits highly efficient loading of RNA-based drugs such as siRNA onto the surface of EVs. Such vesicles efficiently deliver siRNA to target cells in vitro and into the brain of a Huntington's disease mouse model after systemic injection, resulting in silencing of the huntingtin gene in multiple anatomical regions of the brain and modulation of phenotypic features of disease.
During the last decade, a new paradigm of cell-to-cell communication has emerged involving extracellular vesicles (EVs), with implications for both normal and pathological physiology 1, 2 . There are several classes of EVs, but small EVs with a diameter of 30-150 nm are the best studied 3 . They are secreted by cells as exosomes formed in intracellular endosomal compartments or as microvesicles shed from the cell surface. Given their unique biological and pharmacological characteristics, EVs have attracted tremendous interest as mediators of physiological and pathophysiological processes, and as vehicles for drug delivery 4 . Immunological inertness, and ability to cross biological barriers and carry bioactive molecules are attractive features of EVs that can be exploited in drug delivery and therapeutic applications 5, 6 . However, lack of efficient drug loading methods, and an incomplete understanding of EV biogenesis and uptake mechanisms remain critical challenges that need to be addressed 7, 8 . Current methods of loading therapeutic molecules into EVs such as electroporation, genetic engineering of host cells and chemical conjugation, are limited by low efficiency, toxicity and lack of scalability 9, 10 . Moreover, they produce a heterogeneous population of EVs that imposes further complexity in understanding the phenotypic effects of EVs in target cells 11, 12 . It is important to understand the intracellular pathways of EV biogenesis, so that the natural characteristics of EVs can be exploited for therapeutic applications.
In a set of experiments designed to express the N-terminal region of lactoferrin (designated as lactoferrin N) on the surface of EVs, we observed that lactoferrin N, which had been fused to DC-LAMP (Dendritic cell lysosomal associated membrane glycoprotein) to attach it to the surface of EVs, was specifically cleaved from this anchor. Surprisingly, cleaved lactoferrin N was still found associated with the EV surface (Supporting data, Fig.   1 & 2) . Previously, it was demonstrated that cells take up extracellular iron by secreting EVs carrying surface glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which attaches to the iron-binding proteins lactoferrin and transferrin 13 . We confirmed the presence of GAPDH on the outside of EVs isolated from different cell sources using a protease digestion assay (Extended Fig. 1a & 1b) . An enzyme activity assay indicated that this surface GAPDH was enzymatically active (Extended Fig. 1c ). Co-immunoprecipitation experiments of HEK293T cell lysates and EVs demonstrated that the lactoferrin N domain is physically associated with GAPDH in cells and on the surface of EVs (Extended Fig. 1d ). Furthermore, incubation of isolated EVs with purified lactoferrin N protein resulted in efficient binding of the protein to the EV surface. However, incubating purified EVs with a different domain of lactoferrin, the N1.1 domain, which lacks the GAPDH binding motif, did not result in binding to the EV surface (Extended Fig. 1e & Extended Fig. 2a ). Taken together, these experiments demonstrate the role of GAPDH in tethering lactoferrin N on the surface of EVs. To enhance loading of lactoferrin N on to EVs, we increased the GAPDH concentration on the EV surface. Incubation of isolated EVs with GAPDH protein resulted in extensive surface binding of GAPDH, as confirmed by immunoblotting, UVspectrophotometry and GAPDH enzymatic activity (Fig 1a, 1b & Extended Fig. 2c ).
Binding of GAPDH to EVs occurred for all cell sources tested with or without the presence of serum proteins (Extended Fig. 2b-2d ). Interestingly, incubation of EVs with GAPDH resulted in an increase in EV particle size, as determined by nanoparticle tracking analysis (Fig 1c) . Electron microscopy of HEK293T EVs after incubation with GAPDH revealed the formation of long branched chains of EVs (Fig. 1d ). EVs derived from HeLa, B16 F10 and mesenchymal stem cells formed conspicuous thread-like structures when incubated with GAPDH protein, suggesting that GAPDH induces EV aggregation ( Fig. 1e ).
GAPDH isolated from rabbit brain tissues has been reported to induce fusion of synthetic lipid vesicles that contained phosphatidylserine (PS), cholesterol and plasmenylethanolamine 14 . The fusogenic activity of GAPDH can also play an important role in nuclear membrane formation 15, 16 . GAPDH protein was found to bind to the nuclear membrane via a PS-binding domain, designated as G58, located between amino acids 70-90 17 . To determine whether the PS-binding domain of GAPDH is also responsible for mediating binding of GAPDH to the outer surface of EVs, we incubated purified G58 peptide with EVs for 2h at 4 ˚C and then separated EVs from the unbound G58 peptide using gelfiltration chromatography. Binding of G58 peptide to EVs was assessed by western blotting, which revealed extensive binding of the peptide to the EV surface ( Fig. 1f ). Quantification of G58 binding on MSC-and HEK293T-derived EVs revealed approximately 1200 and 1400 G58 peptide binding sites per EV respectively (Extended Fig. 3a-c) . Moreover, binding of G58 did not significantly alter the size of EVs, suggesting that the tetrameric nature of GAPDH is responsible for aggregation of EVs (Fig. 1g) .
To assess the physiological role of GAPDH in EV biology, we exploited a Drosophila melanogaster model of exosome biogenesis. In secondary cells (SCs) of the Drosophila accessory gland (AG), exosomes are formed as intraluminal vesicles (ILVs) in highly enlarged Rab11-positive compartments and then secreted into the lumen of the AG, a storage site for seminal fluid 18, 19 . These ILVs can be selectively marked by fluorescent transmembrane markers, such as a GFP-tagged form of the FGF receptor, Breathless (Btl-GFP). In SCs, ILVs form in clusters that surround a large dense-core granule (DCG) of aggregated protein and extend out to the limiting membrane of the Rab11 compartments 19 .
Drosophila GAPDH is highly conserved and has similar EV binding properties to human GAPDH (Extended Fig. 3d & 3e) . Overexpression of human GAPDH specifically in adult SCs produced larger clusters of Btl-GFP-positive ILVs, an effect also observed when ILVs were marked with a second GFP-tagged transmembrane exosome marker, human CD63 ( Fig.   2b, Extended Fig. 4b ). There was also increased clustering of Btl-GFP and CD63-GFP puncta in the AG lumen, suggesting that human GAPDH promotes vesicle aggregation in vivo (Fig. 2c, Extended Fig. 4b) .
To test the role of GAPDH in normal exosome biogenesis, we knocked down the two Drosophila GAPDH genes in SCs. There was no significant effect of GAPDH1 knockdown on ILV biogenesis, although secretion was reduced ( Fig. 2b, 2c & 2f ).
Figure 2: GAPDH regulates exosome biogenesis and clustering in Drosophila secondary cells: (a)
Schematics show male fruit fly and its accessory gland (AG) containing main cells and secondary cells (SCs), which are only found at the distal tip of the gland. Exosomes can be visualised at the AG lumen as fluorescent puncta. A schematic of a secondary cell expressing a GFP-tagged form of Breathless (Btl-GFP; green) is also shown. The Rab11 compartments, which contain intraluminal vesicles (ILVs; green) and dense-core granules (DCGs; dark grey), and the late endosomes and lysosomes (magenta) are marked. However, GAPDH2 knockdown led to a severe disruption of dense-core granule formation in Rab11 compartments. There was no central dense core, but multiple small dense-core granules formed near the limiting membrane ( Fig. 2b & 2e) . Btl-GFP-labelled ILVs were only located in close proximity to the limiting membrane and around the small DCGs; they were not observed in DCG-independent clusters in the compartment lumen as in controls ( Fig. 2b & 2d) . A similar phenotype was observed with CD63-GFP-marked ILVs, where the proportion of Rab11 compartments making ILVs was also significantly decreased (Extended Figure 4e ). In addition, GAPDH2 knockdown significantly reduced exosome secretion from Rab11 compartments into the AG lumen ( Fig. 2f, Extended Fig. 4f ). This phenotype was not recapitulated by knocking down other enzymes, namely Phosphoglucomutase 2 (Pgm2a), Phosphoglucose isomerase (Pgi) and Phosphofructokinase (Pfk), in the glycolytic pathway, suggesting that the observed effects on EV biogenesis are not a consequence of general metabolic changes (Extended Fig. 5 ). Overall our data indicate that the formation of ILVs and DCGs in Rab11 compartments of SCs may be functionally linked processes that are regulated by GAPDH2. Importantly, inhibition of GAPDH2 expression suppressed the generation of clustered ILVs and their secretion as exosomes, suggesting that this protein normally plays an essential role in exosome biogenesis and aggregation, consistent with the EV clustering phenotype observed upon human GAPDH overexpression.
In light of the physiological role of GAPDH in EV biogenesis, we reasoned that the binding of the GAPDH G58 peptide to the outer surface of EVs could be utilized as a unique, but generic, tool to attach therapeutic moieties to the surface of EVs. As a proof of principle study, we fused the G58 peptide to the double-stranded RNA binding domain (dsRBD) of TAR RNA binding protein 2 (TARBP2), which exhibits high affinity for short doublestranded RNAs such as siRNA 20 . The resulting fusion protein, designated as G58T, was expressed and purified from E.coli cells. Incubation of the protein with purified EVs resulted in high levels of protein binding to EVs (designated as G58T EVs). Gel shift assay and spectrofluorimetric analysis revealed highly efficient binding of the G58T EVs with siRNA (~ 500-700 siRNA molecules per EV). Moreover, bound siRNA was protected from degradation by RNase A (Extended Fig. 6a-c) . Confocal microscopy of N2a cells treated with fluorescently labelled G58T EVs bound Cy-3 siRNA revealed efficient uptake of complexes by the cells (Fig. 3a) . Gene silencing assays using GAPDH predesigned siRNA, however, revealed low levels of gene silencing (~ 15%) in N2a cells treated with G58T EV siRNA (Extended Fig. 6e ). Co-localization studies using lysotracker dye suggested entrapment of delivered siRNA in late endosomes (Extended fig. 6d ). To overcome endosomal entrapment, we investigated the fusion of different endosomolytic peptides including TAT, HA2 and the arginine-rich peptide of flock house nodovirus (FHV) to the G58T protein. These peptides have previously been successfully used to enhance the release of endocytosed drugs from late-endosomes [21] [22] [23] . HA2 fusion protein could not be expressed due to toxicity of the peptide. Attachment of either two TAT peptides or FHV peptide to the G58T protein (designated as G58T(tat)2 and G58TF respectively) resulted in significantly improved activity with ~35% and 60% silencing of endogenous genes (GAPDH and HTT) genes in the cells respectively ( Fig. 3b; Extended Fig. 6g ). Further treatment of cells with chloroquine, an endosomolytic molecule 24 , enhanced gene silencing efficiency to around 80%, consistent with the release of entrapped siRNA from late endosomes ( Fig. 3c;   Extended Fig. 6f & 6h) . Taken together, these results show highly efficient loading and delivery of siRNA into cells by G58T EVs, resulting in potent gene silencing when combined with fusion of endosomolytic peptides to G58T protein.
To further assess the therapeutic potential of G58 engineered EVs in animal models, we investigated targeted delivery of siRNA into the mouse brain by co-expressing the RVG peptide on the EV surface. This peptide, which binds specifically to acetylcholine receptors, has been extensively used to deliver drugs into the brain 25 . Previous studies from our laboratory have shown that RVG increased brain accumulation of EVs without inducing toxicities in mice 26, 27 . To determine whether binding of G58TF protein to the EV surface alters biodistribution of RVG-EVs, we assessed biodistribution of systemically administered RVG-EVs in C57 BL/6 mice. After 4h of administration, a significant fraction of drug dose of RVG-EVs was observed in the whole brains of mice. Binding of either G58TF or G58TF/siRNA to RVG-EVs did not change their biodistribution ( Fig. 3d) , although, as anticipated, the majority of EVs were distributed to peripheral tissues, indicating rapid clearance of EVs from the blood (Extended Fig. 7) .
To assess the silencing efficiency and therapeutic potential of G58TF/siRNA RVG-EVs in the brain, we targeted the huntingtin gene in the Huntington's disease (HD) mouse model Q140. HD is a neurodegenerative disease caused by mutation in the huntingtin gene that results in polyglutamine (poly Q) expansion in the protein, causing death of neurons 28 .
Availability of HD mouse models provides a unique opportunity to assess therapeutic efficiency of siRNA-based drugs in silencing the mutant HTT gene 29 . Using a mixture of siRNAs targeting exon 1 of the HTT gene of Q140 mice, we systemically administered a total of four repeated EV doses weekly over 4 weeks. Analysis of brain tissues revealed almost 40% silencing of the HTT gene in mouse brain cortex and a highly significant decrease of p62 inclusion bodies in the cortical neurons of the treated animals, an important phenotypic HD marker ( Fig. 3f & 3g) . p62 is an important regulatory protein of selective autophagy, and reduction in p62 aggregates in HD mouse models has previously been shown to restore HD-associated phenotypes 30 .
Taken together, our studies demonstrate a novel role for GAPDH protein in EV biogenesis and secretion of EVs from endosomal compartments, which appears to be associated with corresponding loading of GAPDH on EVs that can induce clustering. More importantly, by engineering GAPDH fusion proteins that have retained the G58 EV binding domain, we have developed a simple and highly robust method for therapeutic loading of RNA-based drugs on EVs for targeted drug delivery. These EVs can potentially be generated from any cell type. The method could be extended to deliver other types of cargoes, ranging from different types of nucleic acids including guide RNAs, phosphorodiamidate morpholino oligomers (PMOs), and plasmids to different types of proteins and peptides allowing the therapeutic potential of EVs to be enhanced and extended. The resulting harvest was used for isolation of EVs using differential centrifugation, ultrafiltration and size-exclusion chromatography as described above.
Biophysical characterization of extracellular vesicles (a) Nanosight Tracking Analysis
To measure size distribution and number of extracellular vesicles, nanoparticle tracking analysis was performed with the NS500 nanoparticles analyser (NanoSight, Malvern, Worchestershire, UK), as described previously 31 . Different dilutions of EVs ranging from 1:500 to 1:1000 in PBS were used to achieve a particle count of between 2 10 8 to 2 10 9 ml -1 . During the recordings, a camera level of 12-14 was used. Using a script control function, three 30 s videos of each sample were recorded. After each video, a fresh sample was injected into the stage followed by a delay of 7 s to reduce turbulence of the flow. NTA2.3 software provided by the manufacturer was used to analyse and measure size and concentration of the EVs. All NTA measurements were carried out in triplicate. Data were analysed using GraphPad Prism 8 software.
(b) Electron microscopy of extracellular vesicles:
For electron microscopy of extracellular vesicles, samples were prepared as per the protocol described previously 32 . Briefly 20 µl drops of purified EVs were added to parafilm and formvar-carbon coated EM grids (Agar Scientific, Stansted, UK) were floated on the top of EV droplets for 10 min with the coated side of the grid facing the drop. After the incubation, the grids were carefully transferred to PBS droplets for washing. Finally, the grids were placed briefly on water droplets to remove excess of salts. For contrasting, grids were initially transferred to a 50µl drop of uranyl-oxalate solution, pH 7, for 5 min, followed by embedding in 2% uranyl acetate for 5 min. Next, the grids were carefully removed and excess of fluid was removed by gently pushing the grid sideways on Whatman no. 1 filter paper. The grids were air dried and visualized under a JEOL 1010 transmission electron microscope at 120kV on EFI Tecnai 12 TEM (JEOL, Peabody, MA, USA).
(c) Western blotting of extracellular vesicles:
For western blotting, EV lysates corresponding to 5-10 µg of total protein were run into 4-12% Bis-Tris plus gels (Invitrogen, ThermoFisher Scientific). Prior to loading, EV proteins were denatured by adding NuPAGE™ LDS Sample loading dye and reducing agent (ThermoFisher Scientific) to the EVs and heated at 70˚C for 10 min. Samples loaded on the gel were run at 150V for 1 h in ice-cold NuPAGE™ MES running buffer. Proteins resolved on the gel were transferred onto 0.45 µm Immobilon-P, PVDF Membrane (Millipore), using a mini transfer blot cell (Bio-Rad). Membranes were blocked with SuperBlock™ T20 (TBS) Blocking Buffer (ThermoFisher Scientific) for 1 h at room temperature with gentle shaking.
After blocking, primary antibodies diluted in the blocking buffer were added to the membrane and incubated overnight at 4˚C on a shaker. Details of the antibodies used during the western blotting of EVs are given in the table below. After the incubation, the membranes were washed 3 times for 5 minutes each, using 1X tris-buffered saline, pH 7.6 (TBST, 2.4 g Tris base, 8.8 g of NaCl and 0.1% Tween). After the final wash, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature with gentle shaking. Post-incubation, membranes were washed 3 times for 5 min each with 1X TBST buffer and developed by chemiluminescence (GE healthcare, RPN2106).
The Odyssey FC imaging system (LI-COR) was used to visualize the bands on the membrane. Image studio software provided with the system was used to analyse the data.
For western blotting of proteins from cells, radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher Scientific) containing 1X protease inhibitor (Halt protease inhibitor, ThermoFisher Scientific) was added to cells and incubated on ice for 10 min. Lysates of the cells were passed through 26G needle syringes several times and centrifuged at 12,000g for 20min to remove genomic DNA aggregates and insoluble lipids. Supernatant of the cell lysate corresponding to 5-10 µg of the total proteins were used for the western blotting.
Antibodies Source Dilution
Alix Purification of GAPDH and G58T fusion proteins from bacterial cells.
(a) GAPDH protein
The The DNA sequences of these fusion proteins were cloned into the pET-28b(+) vector. G58T
was expressed in BL21 (DE3) cells, using similar conditions to those mentioned above.
G58T(TAT)2 and G58TF were expressed in BL21 (DE3) Rosetta (Novagen, Merk, USA).
The cells were grown normally at 37˚C until OD600 reached between 0.5 to 0.6. At this point, 0.2mM IPTG was added to the culture, and bacteria were grown at 21˚C for 10 to 12 h. All versions of G58 fusion proteins were purified by Ni-NTA chromatography under denaturing conditions, using 6M urea. Purified proteins were analysed by SDS PAGE and MALDI.
Proteins were refolded by the dilution method. Briefly, proteins bound to Ni-NTA resin were 
Binding of GAPDH and G58T fusion proteins to extracellular vesicles.
For exogenous binding of GAPDH to EVs, purified EVs ranging from 7.5 10 11 particles/ml to 110 12 particles/ml were used for incubation with GAPDH and G58 fusion proteins.
Proteins in the range of 5 to 20nmoles were added to each pmoles of EVs and incubated for 2h at 4˚C on a rotor top. Unbound proteins were removed by gel filtration. Proteins were also added directly to concentrated cell culture media and mice serum for binding followed by gel filtration to remove the unbound proteins from the EVs. Binding of GAPDH proteins to EV surface was monitored by UV-280 chromatogram (Akta pure, GE Healthcare), western blotting, GAPDH kinetic assay and gel-shift assay. 
GAPDH kinetic assay

Gel shift assay and RNase A protection assay.
Binding of G58T, G58T(TAT)2 and G58TF EVs to siRNA was assessed by gel shift assay. 20 pmole of siRNA was added to a given number of EVs in PBS buffer and incubated for 10 min at room temperature. After the incubation, complexes were loaded onto a 2% agarose gel stained with 0.5 µg/ml ethidium bromide for visualization under a UV-illuminator. Binding of siRNA to EVs was determined by analyzing the shift of siRNA on the gel. siRNA bound to EVs remained trapped near the wells while free siRNA migrated freely in the agarose gel.
Using NTA data and the gel binding assay, number of siRNAs bound to EVs was determined.
For the RNase A protection assay, 0.2mg/mL of RNase A (Qiagen) was added to EV-siRNA complexes and incubated for 6 h at 37˚C. The enzyme was inactivated by adding an equal volume of hot SDS lysing solution (2% SDS, 16 mM EDTA) and incubated at 100 0 C for 5 min. siRNA was isolated using TRIzol reagent (Invitrogen, Life Technologies) and
analysed by agarose gel electrophoresis.
Confocal Imaging
To determine uptake of siRNA-loaded EVs into cells, N2a cells were seeded onto coverslips total of 4 doses were given to animals. Animals received each dose weekly. 72h after the last dose, animals were euthanized and different sections of the brain were analyzed for HTT mRNA and protein expression. Levels of HTT mRNA in the saline treated group were assigned as 1 and based on that, the percentage of HTT silencing was determined by using LinRegPCR PfafE1 analysis. For determining the level of HTT protein in the brain tissues, Agarose gel electrophoresis for resolving aggregates (AGERA) was carried out to detect mutant HTT protein aggregates. However, we could not analyze the immunoblot due to high background. Immunohistochemistry of the cortex regions of the brain was carried out to determine the level of mutant HTT protein aggregates and p62 inclusion bodies. Data were analyzed by GraphPad Prism software. Multivariate ANOVA (2 tails) and post-hoc adjustment using Dunnett's test was used to calculate statistical significance between the means of the groups.
In vitro gene silencing by G58-modified extracellular vesicles
Drosophila Stocks and Genetics
The following fly stocks, acquired from the Bloomington Drosophila Stock Centre, unless otherwise stated, were used: UAS-CD63-GFP 34 Flies were reared at 25˚C in vials containing standard cornmeal agar medium (12.5 g agar, 75 g cornmeal, 93 g glucose, 31.5 g inactivated yeast, 8.6 g potassium sodium tartrate, 0.7 g calcium, and 2.5 g Nipagen (dissolved in 12 ml ethanol) per litre. They were transferred onto fresh food every two days. No additional dried yeast was added to the vials.
Temperature-controlled, SC-specific expression of UAS-CD63-GFP and UAS-Btl-GFP was achieved by combining these transgenes with the specific driver, dsx-GAL4 and the temperature-sensitive, ubiquitously expressed repressor tubulin-GAL80 ts . Newly enclosed virgin adult males were transferred to 29˚C to induce post-developmental SC-specific expression. For overexpression and knockdown experiments, the same strategy was employed, but in the presence of a UAS transgene. Six-day-old adult virgin males were used throughout this study to ensure that age-and mating-dependent effects on SC biology were mitigated 18, 19, 39 .
Preparation of Accessory Glands for Live Imaging and Exosome Secretion Analysis
Adult male flies were anaesthetised using CO2. The abdomens were removed from anaesthetised flies and submerged in PBS (Gibco TM ). The whole male reproductive tract was carefully pulled out of the body cavity. The accessory glands were isolated by separation of the ejaculatory bulb from the external genitalia, fat tissues and gut. Finally, the testes were removed by scission close to the seminal vesicles, as they often folded over the accessory glands, obscuring imaging.
The isolated accessory glands were transferred to a 9-spot depression glass plate (Corning ® PYREX ® ) containing ice-cold PBS and kept on ice until sufficient numbers had been obtained. They were then stained with ice-cold 500 nM LysoTracker ® Red DND-99 (Invitrogen ® ) (1:1000) in 1 × PBS for 5 min. Finally, the glands were rinsed in ice-cold PBS before being mounted onto high precision microscope cover glasses. A custom-built holder secured the cover glasses in place during imaging by wide-field microscopy. To avoid dehydration and hypoxia, the glands were carefully maintained in a small drop of PBS, surrounded by 10S Voltalef ® (VWR Chemicals), an oxygen-diffusible hydrocarbon oil 40 , and kept stably in place by the application of a small cover glass (VWR).
Imaging of Drosophila Secondary Cells (SCs) a) Wide-Field Microscopy
For wide-field imaging, living SCs were imaged using a DeltaVision Elite wide-field fluorescence deconvolution microscope (GE Healthcare Life Sciences) equipped with a 100X, NA 1.4 UPlanSApo oil objective lens (Olympus), and a Cool SNAP HQ2 CCD camera (Photometrics ® ). The images acquired were typically z-stacks spanning 8-12 µm depth with a z-distance of 0.2 µm. Images were subsequently deconvolved using the Resolve 3D-constrained iterative deconvolution algorithm within the softWoRx 5.5 software package (GE Healthcare Life Sciences).
b) Confocal Microscopy
Confocal images of accessory glands were acquired by using LSM 880 laser scanning confocal microscope equipped with a 63×, NA 1.4 Plan APO oil DIC objective (Carl Zeiss). RI 1.514 objective immersion oil (Carl Zeiss) was employed.
Drosophila Exosome Secretion Assay
Virgin six-day-old males of each genotype described previously were dissected in 4% paraformaldehyde (Sigma-Aldrich) dissolved in PBS. The glands were left in 4% paraformaldehyde for 15 minutes to preserve the luminal contents before being washed in PBT (PBS containing 0.3% Triton X-100, Sigma-Aldrich) for 5 min. Glands were rinsed with PBS and then mounted onto SuperFrost ® Plus glass slides (VWR), removing excess liquid using a Gilson pipette, and finally immersed in a drop of Vectashield with DAPI (Vector Laboratories) for imaging by confocal microscopy.
Exosome secretion was measured by sampling within the central third of each gland.
Identical microscope settings and equipment were used throughout. At each sampling location, ten different z-planes, spaced by 1 μm and at a distance from any SCs, were analysed.
The automated analysis of exosome secretions by SCs was performed using 
Analysis of ILV Content in Dense-Core Granule Compartments
Living SCs from six-day-old males of each genotype described previously were imaged using identical settings by wide-field microscopy. The total number of dense-core granule (DCG) compartments that contained clustered fluorescently labelled puncta was counted in each cell, using a full z-stack of the epithelium. Three individual SCs were analysed from each of ten to fifteen glands.
Dense-Core Granule Compartment Analysis
Dense-core granule (DCG) compartment numbers were manually quantified in ImageJ2 by using complete z-stacks of individual cells acquired with differential interference contrast (DIC) microscopy on the wide-field microscope. The morphology and position of DCGs were also analysed, and each compartment was categorised by the absence or presence of a single spherical DCG. Three individual SCs per gland from each of ten to fifteen glands were used.
Data Analysis
All data are representative from at least two to three independent experiments. The 
Expression of a lactoferrin-LAMP-2B fusion protein on the surface of extracellular vesicles (EVs) results in cleavage but not release of lactoferrin from the EV surface
To facilitate targeted delivery of EVs into brain, we selected lactoferrin protein for expression on the EV surface. Lactoferrin is an iron-binding protein that is reported to cross the blood-brain barrier via receptor-mediated transcytosis 1, 2 . The N-terminal domain of lactoferrin (designated as lactoferrin N) interacts with the lactoferrin receptor for internalization 3 . We fused lactoferrin N with lysosome-associated membrane protein of dendritic cells (DC-LAMP or LAMP3) to express it on the surface of EVs. During the expression, we noticed cleavage of lactoferrin N from DC-LAMP. Moreover, immunoblotting of HEK293T EVs revealed association of cleaved lactoferrin N with purified EVs (Supporting Fig. 1) . Attachment of green fluorescent protein (GFP) to DC-LAMP did not result in cleavage of GFP from DC-LAMP, suggesting that lactoferrin cleavage could be due to the presence of a specific protease cleavage site in the lactoferrin-DC-LAMP construct (Supporting Fig. 2a, vector 1) . Furthermore, attachment of lactoferrin N to other isoforms of LAMP proteins such as LAMP-2B (DC-LAMP contains only one luminal domain and LAMP-2B contains two luminal domains) did not change the nature of lactoferrin N cleavage, suggesting the specific cleavage site is in lactoferrin N region of the construct (Supporting Fig. 2a, vector 2 &3) . To determine the exact location of the cleavage site, we inserted cMyc and flag tags on either side of the linker sequence of lactoferrin-DC-LAMP (construct 4). Expression of construct 4 in cells confirmed presence of a specific proteolytic cleavage site in the lactoferrin region (Supporting 2a &b). Bioinformatic analysis of the lactoferrin sequence, using Protease Specificity Prediction Server (PROSPER), revealed the presence of a specific group II cleavage site (L/IXX/Xhyd) of matrix metalloproteinase-2 (MMP-2) near the C-terminus of lactoferrin N, consistent with the molecular weight of cleaved lactoferrin N protein. A group IV cleavage site (XhydSX/L, S and L are invariant) of MMP-2 was also detected by PROSPER near the N-terminus of the lactoferrin (Supporting Fig. 2c ). However, lack of an important isoleucine renders it less prone to cleavage by MMP-2 4 . To assess whether MMP-2 is responsible for cleavage of the lactoferrin N, we mutated the group II cleavage site and fused a cMyc tag to the N-terminus of lactoferrin N. The protein expressed from this construct in HEK293T was not cleaved (Supporting Fig. 2d) . The fulllength lactoferrin-LAMP-2B protein was detected with cMyc and lactoferrin antibodies indicating that MMP-2 also does not cleave the group IV site. Immunoblotting of HEK293T EVs revealed the association of MMP-2 with EVs ( Supplementary Fig. 2e ). Taken together, the data suggest cleavage of the protein by MMP-2 enzyme. Although it seems likely that cleavage is occurring on the surface of EVs during EV biogenesis, it remains possible that lactoferrin is cleaved in the cell cytoplasm, and later trafficked to the EV surface by GAPDH protein, which tethers cleaved lactoferrin to the surface of EVs, as explained in other parts of the manuscript.
